At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 52 enrolled
Drug / intervention
Dasatinib +1 moredrug
Likely dose
Dasatinib 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Advanced Breast Cancer
In Brief
A Phase 1 clinical trial evaluating Dasatinib and Capecitabine for Advanced Breast Cancer. Completed, enrolled 52 participants across 7 sites in 3 countries.
Detailed Summary
The purpose of this study is to learn about the safety and efficacy of Dasatinib in combination with Capecitabine for patients with advanced breast cancer, and who have received treatment with a taxane and an anthracycline
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Breast Cancer
CountriesItaly, Spain, United States
Collaborators--
Timeline
Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2007
Enrollment StartJun 2007
Primary CompletionOct 2012
TodayJul 2026
First PostedMar 27, 2007
Enrollment StartJun 1, 2007
Primary CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 19.3 years ago
Interventions
Dasatinibdrug
Tablets, Oral, 50 mg or 70 mg twice a day (BID), 100 mg once per day (QD). Treatment may continue until disease progression
Capecitabinedrug
Tablets, Oral, 660 - 1250 mg/m\^2 twice a day (BID). Treatment may continue until disease progression.